Search Results - "Pomej, Katharina"

Early changes in immunoglobulin G levels during immune checkpoint inhibitor treatment are associated with survival in hepatocellular carcinoma patients by Balcar, Lorenz, Bauer, David, Pomej, Katharina, Meischl, Tobias, Mandorfer, Mattias, Reiberger, Thomas, Trauner, Michael, Scheiner, Bernhard, Pinter, Matthias

“…Immunotherapy represents the new standard of care in systemic first-line treatment of hepatocellular carcinoma (HCC). Biomarkers that predict treatment…”
Get full text

COVID-19 pandemic: Impact on the management of patients with hepatocellular carcinoma at a tertiary care hospital by Pomej, Katharina, Scheiner, Bernhard, Hartl, Lukas, Balcar, Lorenz, Meischl, Tobias, Mandorfer, Mattias, Reiberger, Thomas, Müller, Christian, Trauner, Michael, Pinter, Matthias

“…Background Patients with hepatocellular carcinoma (HCC) represent a vulnerable population potentially negatively affected by COVID-19-associated reallocation…”
Get full text

Management of varices but not anticoagulation is associated with improved outcome in patients with HCC and macrovascular tumour invasion by Balcar, Lorenz, Mrekva, Arpad, Scheiner, Bernhard, Pomej, Katharina, Meischl, Tobias, Mandorfer, Mattias, Reiberger, Thomas, Trauner, Michael, Tamandl, Dietmar, Pinter, Matthias

“…The value of bleeding prophylaxis and anticoagulation in patients with hepatocellular carcinoma (HCC) and macrovascular tumour invasion (MVI) is unclear. We…”
Get full text

COVID‐19‐Related Downscaling of In‐Hospital Liver Care Decreased Patient Satisfaction and Increased Liver‐Related Mortality by Hartl, Lukas, Semmler, Georg, Hofer, Benedikt Silvester, Schirwani, Nawa, Jachs, Mathias, Simbrunner, Benedikt, Bauer, David Josef Maria, Binter, Teresa, Pomej, Katharina, Pinter, Matthias, Trauner, Michael, Mandorfer, Mattias, Reiberger, Thomas, Scheiner, Bernhard

“…The coronavirus disease 2019 (COVID‐19) pandemic necessitated down‐scaling of in‐hospital care to prohibit the spread of severe acute respiratory…”
Get full text

A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma by Balcar, Lorenz, Scheiner, Bernhard, Fulgenzi, Claudia Angela Maria, D’Alessio, Antonio, Pomej, Katharina, Roig, Marta Bofill, Meyer, Elias Laurin, Che, Jaekyung, Nishida, Naoshi, Lee, Pei-Chang, Wu, Linda, Ang, Celina, Krall, Anja, Saeed, Anwaar, Stefanini, Bernardo, Cammarota, Antonella, Pressiani, Tiziana, Abugabal, Yehia I., Chamseddine, Shadi, Wietharn, Brooke, Parisi, Alessandro, Huang, Yi-Hsiang, Phen, Samuel, Vivaldi, Caterina, Salani, Francesca, Masi, Gianluca, Bettinger, Dominik, Vogel, Arndt, von Felden, Johann, Schulze, Kornelius, Silletta, Marianna, Trauner, Michael, Samson, Adel, Wege, Henning, Piscaglia, Fabio, Galle, Peter R., Stauber, Rudolf, Kudo, Masatoshi, Singal, Amit G., Itani, Aleena, Ulahannan, Susanna V., Parikh, Neehar D., Cortellini, Alessio, Kaseb, Ahmed, Rimassa, Lorenza, Chon, Hong Jae, Pinato, David J., Pinter, Matthias

“…Sex-related differences in the immune pathogenesis of hepatocellular carcinoma (HCC), particularly related to oestrogen-dependent secretion of pro-tumourigenic…”
Get full text

Palliative care in terminally ill advanced chronic liver disease patients by Pomej, Katharina, Masel, Eva Katharina, Kreye, Gudrun

“…While mortality rates from advanced chronic liver disease (ACLD) are rapidly increasing, patients with an advanced disease stage have a comparable or even…”
Get full text

NASH limits anti-tumour surveillance in immunotherapy-treated HCC by Pfister, Dominik, Núñez, Nicolás Gonzalo, Govaere, Olivier, Pinter, Matthias, Szydlowska, Marta, Qiu, Mengjie, Deczkowska, Aleksandra, Weiner, Assaf, Müller, Florian, Sinha, Ankit, Friebel, Ekaterina, Engleitner, Thomas, Lenggenhager, Daniela, Moncsek, Anja, Heide, Danijela, Stirm, Kristin, Kosla, Jan, Kotsiliti, Eleni, Leone, Valentina, Dudek, Michael, Yousuf, Suhail, Inverso, Donato, Singh, Indrabahadur, Teijeiro, Ana, Castet, Florian, Montironi, Carla, Haber, Philipp K., Tiniakos, Dina, Bedossa, Pierre, Cockell, Simon, Younes, Ramy, Marra, Fabio, Schattenberg, Jörn M., Allison, Michael, Bugianesi, Elisabetta, Ratziu, Vlad, D’Alessio, Antonio, Personeni, Nicola, Rimassa, Lorenza, Daly, Ann K., Scheiner, Bernhard, Pomej, Katharina, Kirstein, Martha M., Peck-Radosavljevic, Markus, Hucke, Florian, Finkelmeier, Fabian, Trojan, Jörg, Schulze, Kornelius, Wege, Henning, Koch, Sandra, Weinmann, Arndt, Bueter, Marco, Rössler, Fabian, Siebenhüner, Alexander, Mallm, Jan-Philipp, Umansky, Viktor, Jugold, Manfred, Luedde, Tom, Schietinger, Andrea, Schirmacher, Peter, Emu, Brinda, Augustin, Hellmut G., Billeter, Adrian, Müller-Stich, Beat, Kikuchi, Hiroto, Duda, Dan G., Waldschmidt, Dirk-Thomas, Rahbari, Nuh, Mei, Henrik E., Schulz, Axel Ronald, Ringelhan, Marc, Malek, Nisar, Spahn, Stephan, Bitzer, Michael, Ruiz de Galarreta, Marina, Lujambio, Amaia, Dufour, Jean-Francois, Marron, Thomas U., Kaseb, Ahmed, Kudo, Masatoshi, Huang, Yi-Hsiang, Djouder, Nabil, Wolter, Katharina, Zender, Lars, Decaens, Thomas, Pinato, David J., Rad, Roland, Mertens, Joachim C., Weber, Achim, Unger, Kristian, Meissner, Felix, Roth, Susanne, Jilkova, Zuzana Macek, Claassen, Manfred, Anstee, Quentin M., Amit, Ido, Knolle, Percy, Becher, Burkhard, Llovet, Josep M., Heikenwalder, Mathias

“…Hepatocellular carcinoma (HCC) can have viral or non-viral causes 1 – 5 . Non-alcoholic steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has…”
Get full text

Reply to comment: Von Willebrand factor measurement during acute decompensation by Mandorfer, Mattias, Pomej, Katharina, Scheiner, Bernhard, Balcar, Lorenz, Reiberger, Thomas

Get full text

Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score by Scheiner, Bernhard, Pomej, Katharina, Kirstein, Martha M., Hucke, Florian, Finkelmeier, Fabian, Waidmann, Oliver, Himmelsbach, Vera, Schulze, Kornelius, von Felden, Johann, Fründt, Thorben W., Stadler, Marc, Heinzl, Harald, Shmanko, Kateryna, Spahn, Stephan, Radu, Pompilia, Siebenhüner, Alexander R., Mertens, Joachim C., Rahbari, Nuh N., Kütting, Fabian, Waldschmidt, Dirk-Thomas, Ebert, Matthias P., Teufel, Andreas, De Dosso, Sara, Pinato, David J., Pressiani, Tiziana, Meischl, Tobias, Balcar, Lorenz, Müller, Christian, Mandorfer, Mattias, Reiberger, Thomas, Trauner, Michael, Personeni, Nicola, Rimassa, Lorenza, Bitzer, Michael, Trojan, Jörg, Weinmann, Arndt, Wege, Henning, Dufour, Jean-François, Peck-Radosavljevic, Markus, Vogel, Arndt, Pinter, Matthias

“…Immunotherapy with atezolizumab plus bevacizumab represents the new standard of care in systemic front-line treatment of hepatocellular carcinoma (HCC)…”
Get full text

On treatment alpha-fetoprotein reductions predict immunotherapy efficiency in patients with hepatocellular carcinoma by Scheiner, Bernhard, Pomej, Katharina, Balcar, Lorenz, Meischl, Tobias, Müller, Christian, Trauner, Michael, Pinter, Matthias

Get full text

Management of varices but not anticoagulation is associated with improved outcome in patients with hepatocellular carcinoma and macrovascular tumour invasion by Balcar, Lorenz, Mrekva, Arpad, Scheiner, Bernhard, Pomej, Katharina, Meischl, Tobias, Mandorfer, Mattias, Reiberger, Thomas, Trauner, Michael, Tamandl, Dietmar, Pinter, Matthias

Get full text

FRI-285 - Management of varices but not anticoagulation is associated with improved outcome in patients with hepatocellular carcinoma and macrovascular tumour invasion by Balcar, Lorenz, Mrekva, Arpad, Scheiner, Bernhard, Pomej, Katharina, Meischl, Tobias, Mandorfer, Mattias, Reiberger, Thomas, Trauner, Michael, Tamandl, Dietmar, Pinter, Matthias

Get full text

TOP-488-YI Fecal microbiota transplant combined with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma who progressed on atezolizumab plus bevacizumab-interim analysis of the FAB-HCC phase II pilot study by Pomej, Katharina, Frick, Adrian, Scheiner, Bernhard, Balcar, Lorenz, Pajancic, Larissa, Klotz, Anton, Regnat, Katharina, Zinober, Kerstin, Trauner, Michael, Tamandl, Dietmar, Gasche, Christoph, Pinter, Matthias

Get full text

Safety of direct oral anticoagulants in patients with advanced liver disease by Semmler, Georg, Pomej, Katharina, Bauer, David J. M., Balcar, Lorenz, Simbrunner, Benedikt, Binter, Teresa, Hartl, Lukas, Becker, Jeannette, Pinter, Matthias, Quehenberger, Peter, Trauner, Michael, Mandorfer, Mattias, Lisman, Ton, Reiberger, Thomas, Scheiner, Bernhard

“…Background & Aims While direct oral anticoagulants (DOACs) are increasingly used in patients with liver disease, safety data especially in advanced chronic…”
Get full text

Outcome of Budd-Chiari Syndrome Patients Treated With Direct Oral Anticoagulants: An Austrian Multicenter Study by Semmler, Georg, Lindorfer, Alexander, Schäfer, Benedikt, Bartl, Stefan, Hametner-Schreil, Stephanie, Gensluckner, Sophie, Balcar, Lorenz, Pomej, Katharina, Lampichler, Katharina, Trauner, Michael, Aigner, Elmar, Datz, Christian, Zoller, Heinz, Hofer, Harald, Schöfl, Rainer, Mandorfer, Mattias, Reiberger, Thomas, Scheiner, Bernhard

“…Direct oral anticoagulants (DOACs) may simplify management of Budd-Chiari syndrome (BCS). Here, we report our experience with off-label use of DOACs for…”
Get full text

Clinical Course of Porto-Sinusoidal Vascular Disease Is Distinct From Idiopathic Noncirrhotic Portal Hypertension by Wöran, Katharina, Semmler, Georg, Jachs, Mathias, Simbrunner, Benedikt, Bauer, David Josef Maria, Binter, Teresa, Pomej, Katharina, Stättermayer, Albert Friedrich, Schwabl, Philipp, Bucsics, Theresa, Paternostro, Rafael, Lampichler, Katharina, Pinter, Matthias, Trauner, Michael, Mandorfer, Mattias, Stift, Judith, Reiberger, Thomas, Scheiner, Bernhard

“…Porto-sinusoidal vascular disease (PSVD) was recently proposed as novel clinical entity characterized by typical histological changes with or without portal…”
Get full text

SAT-106 Gadoxetic acid-enhanced MRI-derived functional liver imaging score (FLIS) predicts acute-on-chronic liver failure in patients with acute decompensation by Balcar, Lorenz, Poetter-Lang, Sarah, Ba-Ssalamah, Ahmed, Bastati, Nina, Ambros, Raphael, Kristic, Antonia, Krawanja, Julia, Pomej, Katharina, Simbrunner, Benedikt, Semmler, Georg, Schmidbauer, Viktor, Pochepnia, Svitlana, Sobotka, Daniel, Hodge, Jacqueline, Trauner, Michael, Reiberger, Thomas, Beer, Lucian, Mandorfer, Mattias

Get full text

Sarcopenia impairs survival and treatment efficacy in patients with hepatocellular carcinoma undergoing immunotherapy by Scheiner, Bernhard, Lampichler, Katharina, Pomej, Katharina, Beer, Lucian, Balcar, Lorenz, Meischl, Tobias, Müller, Christian, Trauner, Michael, Scharitzer, Martina, Tamandl, Dietmar, Pinter, Matthias

Get full text

Smoking and obesity promote systemic inflammation in patients with compensated and decompensated cirrhosis by Hofer, Benedikt, Simbrunner, Benedikt, Semmler, Georg, Schwarz, Michael, Balcar, Lorenz, Hartl, Lukas, Jachs, Mathias, Pomej, Katharina, Paternostro, Rafael, Müllner-Bucsics, Theresa, Schwabl, Philipp, Scheiner, Bernhard, Trauner, Michael, Mandorfer, Mattias, Reiberger, Thomas

Get full text

WED-334 - Smoking and obesity promote systemic inflammation in patients with compensated and decompensated cirrhosis by Hofer, Benedikt, Simbrunner, Benedikt, Semmler, Georg, Schwarz, Michael, Balcar, Lorenz, Hartl, Lukas, Jachs, Mathias, Pomej, Katharina, Paternostro, Rafael, Müllner-Bucsics, Theresa, Schwabl, Philipp, Scheiner, Bernhard, Trauner, Michael, Mandorfer, Mattias, Reiberger, Thomas

Get full text